The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence
Open Access
- 20 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (31) , 2110-2118
Abstract
The 2013 American College of Cardiology/American Heart Association cholesterol guideline was a major paradigm shift and heavily criticized by some experts. A better understanding of the methodology used to develop the guideline, the guideline recommendations, and the evidence supporting them addresses many of criticisms. An extensive body of evidence from randomized clinical trials supports the new risk-based approach. The emphasis is on the appropriate intensity of statin therapy in patients most likely to benefit. The National Institute for Health and Care Excellence guidelines have taken a similar approach. Recent studies have found the 2013 guideline outperforms earlier cholesterol guidelines recommending low-density lipoprotein cholesterol (LDL-C) treatment thresholds and targets. The 2013 cholesterol guideline better identifies high-risk patients with a greater burden of atherosclerosis and avoids treating those at lower risk with little atherosclerosis; its application would prevent up to 450 000 more atherosclerotic cardiovascular disease (ASCVD) events over 10 years. The 2013 cholesterol guideline also recommends regularly monitoring LDL-C levels to assess adherence to lifestyle and drug therapy, and adjusting treatment based on response to therapy and adverse events. Non-statins shown to reduce ASCVD events when added to statin therapy, and that have an acceptable margin of safety in randomized, controlled clinical trials, are preferred. Ezetimibe has now been shown to meet this standard. The concept of net benefit introduced in the 2013 ACC/AHA cholesterol guideline identifies patients most likely to benefit from statin therapy to reduce ASCVD risk. Net benefit, incorporating the absolute ASCVD risk of a patient and the relative reduction in ASCVD risk based on the magnitude of LDL-C reduction from the addition of a non-statin, can be used when considering whether to add ezetimibe or another LDL-C lowering drug.Keywords
This publication has 32 references indexed in Scilit:
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJACC, 2014
- 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular RiskJACC, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJACC, 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014
- An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemiaJournal of Clinical Lipidology, 2013
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and AtherosclerosisJACC, 2013
- Journey Through Cholesteryl Ester Transfer Protein InhibitionCirculation: Cardiovascular Quality and Outcomes, 2013
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyNew England Journal of Medicine, 2011
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005